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The aim of this study was to analyze clinical aspects, hearing evolution and efficacy of clinical treatment of patients with sudden
sensorineural hearing loss (SSNHL). This was a prospective clinical study of 136 consecutive patients with SSNHL divided into
three groups after diagnostic evaluation: patients with defined etiology (DE, N = 13, 10%), concurrent diseases (CD, N = 63,
46.04%) and idiopathic sudden sensorineural hearing loss (ISSHL, N = 60, 43.9%). Initial treatment consisted of prednisone and
pentoxifylline. Clinical aspects and hearing evolution for up to 6 months were evaluated. Group CD comprised 73% of patients
with metabolic decompensation in the initial evaluation and was significantly older (53.80 years) than groups DE (41.93 years)
and ISSHL (39.13 years). Comparison of the mean initial and final hearing loss of the three groups revealed a significant hearing
improvement for group CD (P = 0.001) and group ISSHL (P = 0.001). Group DE did not present a significant difference in
thresholds. The clinical classification for SSNHL allows the identification of significant differences regarding age, initial and final
hearing impairment and likelihood of response to therapy. Elevated age and presence of coexisting disease were associated
with a greater initial hearing impact and poorer hearing recovery after 6 months. Patients with defined etiology presented a much
more limited response to therapy. The occurrence of decompensated metabolic and cardiovascular diseases and the possibility
of first manifestation of auto-immune disease and cerebello-pontine angle tumors justify an adequate protocol for investigation
of SSNHL.
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Introduction
The term sudden deafness is frequently used in the
scientific literature; however, its definition is neither pre-
cise nor completely adequate to describe sudden senso-
rineural hearing loss (SSNHL), which is still commonly
confused with idiopathic sudden deafness. Furthermore,
there is no universally accepted definition of what consti-
tutes SSNHL, either in terms of the amount of hearing loss
or the time interval during which it must develop. To com-
pare literature data and analyze our cases, we have cho-
sen the most frequently used definition of sudden deaf-
ness: the loss of hearing of at least 30 dB over at least 3
contiguous test frequencies occurring within 3 days (1,2).
It is important to emphasize that this is a definition of one
symptom and, since 1944 when De Kleyn (3) first reported
SSNHL, the scientific community is still searching for an-
swers regarding the clinical aspects, treatment and evolu-
tion of SSNHL. As a symptom, SSNHL can be found in
several diseases such as temporal bone or cerebello-
pontine angle tumors, inflammatory inner ear disorders
and Ménière’s disease (4).
Usually, no etiology can be identified after clinical
evaluation, even after using a significant number of diag-
nostic tools, including magnetic resonance imaging (MRI)
(5). Under these circumstances, after an adequate etio-
logical search, the hearing loss can be termed idiopathic.
However, the low specificity and high cost of the comple-
mentary exams currently available do not stimulate the
interest in establishing an etiologic diagnosis. The identifi-
cation of cases with specific and treatable causes is critical
to undertaking optimum management and obtaining the
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most favorable outcome.
SSNHL can also occur in patients presenting concur-
rent diseases such as hypertension, diabetes and dyslipi-
demia where a causal relation with cochlear damage is
uncertain but probable (6).
In this prospective study, we investigated the clinical
aspects, hearing evolution and possible efficacy of clinical
treatment in three different groups of patients with SSNHL:
patients with defined etiology, patients with concurrent
diseases and patients with unknown etiology (idiopathic).
Patients and Methods
One hundred and thirty-six consecutive patients (139
ears) who developed hearing losses of at least 30 dB in
three contiguous frequencies during a period of no more
than 3 days were evaluated in our Department between
March 2000 and December 2006. All patients were seen
within 20 days of the onset of hearing loss and none
received prior treatment.
All patients underwent a standard evaluation consist-
ing of a detailed medical history and physical examination,
audiometric testing, blood tests, and imaging study.
The Federal University of São Paulo Ethics Committee
approved the research (#0316/08) and written informed
consent was given by the patients.
Audiometric tests consisted of pure-tone audiometry,
speech audiometry (speech reception threshold test and
speech discrimination score), and tympanometry curve
with determination of acoustic reflexes. The hearing in-
volvement was monitored by successive audiometric ex-
aminations: on the day of presentation, weekly during the
1st month, and at 3 and 6 months after presentation. A pure
tone average of 500, 1000, 2000, and 4000 Hz was used to
categorize the losses as mild (26-40 dB), moderate (41-70
dB), severe (71-90 dB), profound (>90 dB), or total.
MRI images of the encephalon with emphasis on the
temporal bone and posterior fossa were obtained in a
sequence concentrated on T1 Turbo Spin Echo (TSE) on
axial and coronal planes, with and without contrast, in 1.0-
mm thick sections. T2 images on the coronal plane in TSE
and 3-D using 0.7-mm reconstructions were also col-
lected. The exam was completed with axial sections in a
concentrated sequence in fluid attenuation inversion re-
covery to assess the brain.
Initial laboratory tests included complete blood count,
determination of fasting glucose, total and fractionated
cholesterol and triglycerides, and erythrocyte sedimenta-
tion rate. All exams were performed before or on the first
day of treatment.
During follow-up, some complementary investigations
such as distortion product otoacoustic emissions, electro-
cochleography, laboratory tests for HSP 70 protein (68
kD), rheumatologic tests (anti-nucleus factor), determina-
tion of complement and viral serology (mumps, herpes
simplex types I and II, varicella zoster, cytomegalovirus,
HIV, and mononucleosis) were carried out in cases of
worsening of hearing thresholds or changes in patient
clinical condition, or based on the results of MRI.
The diagnosis of Ménière disease followed the criteria
defined by the Committee on Hearing and Equilibrium of
the American Academy of Otolaryngology - Head and
Neck Surgery Foundation (7).
The patients were divided into three groups: SSNHL
with defined etiology (DE), SSNHL with concurrent dis-
ease (CD), and idiopathic sudden sensorineural hearing
loss (ISSHL) according to the results of clinical, imaging,
and biochemical evaluations.
All subjects received prednisone and pentoxifylline
after the first evaluation. The initial dosage of prednisone
was 1 mg/kg (60 mg/day maximum) by mouth daily for 5
days, then tapered-off and discontinued after 15 days. Oral
pentoxifylline at the dose of 1200 mg/day divided into three
doses was initiated together with prednisone and contin-
ued for a minimum of 4 and a maximum of 8 weeks. All
patients were treated as outpatients. Patients who re-
quired specific therapy for diabetes, hypertension and
dyslipidemia were treated in association with the proposed
standard therapy. No surgical intervention was performed
during the 6-month period of follow-up.
The percentage of hearing recovery was calculated
using the following measurement: recovery rate (%) =
(initial mean threshold - final mean threshold) x 100 / (initial
mean threshold - 25).
Using 25 dB (hearing level) as normal hearing thresh-
old allows a universal use of this form of hearing restora-
tion measurement, even in cases with bilateral involve-
ment when the use of contralateral side as reference is
not possible (8). The mean arithmetical initial and final
hearing threshold was calculated based on thresholds of
500, 1000, 2000, and 4000 Hz. Recovery rates over 90%
were considered total recovery and values between 21
and 90% were considered as partial recovery. Values
below 20% represented lack of recovery, whereas nega-
tive values denoted worsening of hearing thresholds (4).
To assess the supposed effect of treatment and hearing
evolution we compared the initial and final hearing thresh-
olds at 6 months in the three groups using the ANOVA
statistical method. The Pearson χ2 test was employed to
assess differences in gender composition among the 3
groups. The mean age of the three groups was also
compared.
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Results
We identified a definite etiology for the sudden hearing
loss (group DE) in 13 subjects with 14 involved ears (10%).
There were 6 cases of Ménière’s disease, 3 cases of
acoustic schwannoma, 1 case of temporal bone menin-
gioma, 1 case of cochlear inflammatory disease, 1 case of
mumps, and 1 case of Cogan syndrome that involved both
ears. The case of cochlear auto-immune disease was
identified by MRI and subsequently confirmed by meas-
urement of HSP 70. The patient with mumps developed
hearing loss during the course of the clinical disease and
also exhibited inflammatory cochlear MRI findings. MRI
also discovered the VIII schwannoma and the menin-
gioma; the clinical evolution and audiometry identified the
patients with Ménière’s disease, and biochemical tests,
clinical history and ophthalmologic examination identified
the case of Cogan syndrome.
A concurrent disease (CD group) was identified in 63
subjects with 64 involved ears (46%): hypertension (42
ears with one bilateral case), diabetes (18 ears), dyslipide-
mia (6 ears), upper airway infection with normal inner ear
MRI (6 ears), arthritis (4 ears), arrhythmia (3 ears), thyroid
disease (3 ears), chronic renal insufficiency (2 ears), coro-
nary insufficiency (2 ears), systemic lupus erythematosus
(1 ear), and convulsive crisis (1 ear). More than one
coexistent disease was evident in some subjects and 73%
of the patients from this group presented metabolic de-
compensation at the initial evaluation.
Sixty subjects with 61 involved ears (43.9%) had no
specific etiology or concurrent disease and comprised the
ISSHL group. The presence of tinnitus was observed in
78% of DE cases, 87% of CD cases, and 87% of ISSHL
cases. Vertigo or imbalance was detected in 56% of DE
cases, 43% of CD cases and 39% of ISSHL cases.
There was no significant difference in age between the
DE (41.93 years) and ISSHL (39.13 years) groups. How-
ever, the CD group was significantly older (53.80 years)
than DE (P = 0.016) and ISSHL groups (P = 0.001). The
Pearson χ2 test detected no difference in gender composi-
tion among the 3 groups (P = 0.256).
In the DE group, the hearing loss at presentation was
classified as mild in 21.4% of the 14 ears, moderate in
50%, severe in 21.4%, and profound in 7.1%. None of the
ears exhibited a total hearing loss in this group. For group
DE as a whole, the mean auditory threshold at presenta-
tion was 59.6 dB and the final mean threshold was 56.9 dB.
The hearing loss was totally recovered in 28.6%, partially
recovered in 21.4%, remained essentially unchanged in
21.4%, and worsened in 28.6%. These percentages were
similar across the subjects, with no correlation with initial
hearing loss.
In the CD group (64 ears), 9.4% of the patients initially
presented a mild hearing loss, 28.1% a moderate loss,
15.6% a severe loss, 31.3% a profound loss, and 15.6%
had a total hearing loss in the involved ear. The initial and
final mean auditory thresholds for the CD group as a whole
were 82.7 and 66.3 dB, respectively. In this group, 10.3%
experienced total hearing recovery, 48.3% had partial
recovery, 34.5% maintained the initial hearing levels, and
6.9% worsened.
The initial audiograms of the 61 ears in the ISSHL
group showed mild hearing loss in 4.9%, moderate in
47.5%, severe in 23%, profound in 16.4%, and total in
8.2%. Forty-four percent of these ears achieved total re-
covery of hearing at 6 months and 28% had partial im-
provement. There was no recovery in 22% and hearing
worsened in 6%. The initial mean auditory threshold in this
group was 74.5 dB and the final mean threshold was 44.9
dB.
Comparing the mean initial and final hearing loss for
the three groups (marginal homogeneity test), a significant
hearing improvement was observed for the CD (P = 0.001)
and ISSHL (P = 0.001) groups. However, group DE did not
show a statistically significant difference in hearing thresh-
olds (Figure 1).
Discussion
Sudden sensorineural hearing loss is an intriguing
clinical condition. It remains difficult to understand the
outcomes of the natural history and the efficacy of different
treatments for many reasons, including differences in stan-
dardization of its definition, different outcome measures
studied, differences in patient demographics, and the ex-
istence of multiple factors involved in its genesis (9). In the
Figure 1. Mean initial and final auditory thresholds of the three
groups.
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present study, the degree of initial hearing loss was not
evaluated as a prognostic item; the aim was to emphasize
the etiology of cochlear aggression. Our protocol of inves-
tigation allowed us to identify a specific etiology in only
10% of cases. Nonetheless, the prognosis for hearing
recovery was poorer in this group of patients with no
significant hearing improvement, although some cases did
improve using only the standard initial treatment, including
two patients with vestibular schwannomas and one with a
meningioma. The behavior of these patients was similar to
that of the ISSHL group, emphasizing the importance of
complete evaluation of all cases of sudden hearing loss
(10,11). The patients with Ménière disease and autoim-
mune disorders received specific therapy after the identifi-
cation of these alterations. In the patient with Cogan syn-
drome, the hearing loss was the first symptom, again
emphasizing the necessity of a complete investigation in
patients with sudden hearing loss. Despite the effort to
control the basic problem, no hearing improvement was
observed in this group during a 6-month follow-up, sug-
gesting that these specific diseases may promote chronic
aggression to the inner ear and/or cochlear nerve, allowing
limited hearing recovery.
Unfortunately, nearly 90% of our cases did not have an
established etiology, but interestingly, when these patients
were divided into subjects with concomitant disease and
subjects without any other contributing factor, three signifi-
cant findings were obtained: CD patients were older and
had greater initial hearing impact and poorer hearing re-
covery at the conclusion of the study, although an impor-
tant improvement occurred with the initial treatment regi-
men and associated therapy for the underlying disease
initiated as soon as an affirmative diagnosis was possible
(Figure 1).
Although assigning specific mechanisms for the hearing
loss of these patients is only speculative, diseases such as
diabetes, hypertension, dyslipidemia, and viral infection might
have important effects on the physiopathology of hearing
involvement through microvascular disturbances and co-
chlear inflammatory processes (12-14). The possibility of
cochlear vascular involvement in these cases justified the
use of pentoxifylline in our treatment regimen, but it is
impossible to conclude from our study if the medication
played an important role in the hearing recovery.
Although all CD patients with diabetes, dyslipidemia
and hypertension were aware of their diseases, most of
them presented clear decompensated status during the
initial evaluation, representing evidence of inadequate
treatment maintenance. The control of concurrent dis-
eases provided an improvement of hearing level, even
though not as significant as observed in patients without
metabolic and vascular disorders. The occurrence of sud-
den hearing loss in these patients was important by calling
attention to a more rigid control of those primary diseases.
The importance of age and the incidence of diabetes
and hypertension in patients of the present study deserve
some comments. According to the Brazilian Endocrinology
Society, diabetes is found in 7.6% of the Brazilian general
population between 30 and 69 years of age, but reaches
12.7% between ages 50 and 59. The CD group presented
a mean age of 53.8 years and 12.9% of these patients had
diabetes. In this same group, 30.2% had associated hyper-
tension, which affects 20% of the Brazilian general popula-
tion and up to 47.8% of Brazilians between ages 50 and 59.
These data suggest that, although an expressive number
of diabetic and hypertensive patients were detected in the
CD group, the frequency of these diseases in SSNHL is
comparable to that for the general Brazilian population of
similar age. In conclusion, these vascular and metabolic
disorders may contribute to the onset of, and can be a risk
factor for, SSNHL but further prospective studies are needed
to confirm the true effects of these metabolic diseases on
the evolution of hearing loss.
The occurrence of decompensated metabolic and car-
diovascular diseases and the possibility of first manifesta-
tion in autoimmune disease and in cerebello-pontine angle
tumors justify an adequate protocol of investigation in
patients with SSNHL.
In 61 instances, the cause of SSNHL remained un-
known. We presume that the diagnosis of SSNHL will
improve in the future with new and better testing (15). At
present, a battery of studies similar to those described
here provide a quick way to identify both the specific
causes and concurrent diseases, which require specific
medical intervention.
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